Karin Hansson
Chief Executive Officer at Scandibio Therapeutics AB
Profile
Dr. Karin M.
Hansson is a Chief Executive Officer & Director at Amylonix AB, a Chief Executive Officer at Scandibio Therapeutics AB, a Chief Executive Officer & Director at Scandiedge Therapeutics AB, a Chief Executive Officer at A05 Diagnostics AB, a Chief Executive Officer at Zytox Therapeutics AB, a Chief Executive Officer & Director at Mariham Consulting AB and a Chief Executive Officer & Director at Protemedge AB.
She is on the Board of Directors at Amylonix AB, Scandiedge Therapeutics AB, Mariham Consulting AB and Protemedge AB.
Dr. Hansson was previously employed as an Independent Director by Intervacc AB, an Independent Director by Q-linea AB, a Chief Executive Officer by Atlas Antibodies AB, a Principal by Affibody AB, a Manager-Business Development by Affibody Medical AB, and a Deputy Director by Antibodies Incentive AB.
She also served on the board at Atlas Therapeutics AB.
She received her graduate degree from Royal Institute of Technology and a doctorate degree from Royal Institute of Technology.
Karin Hansson active positions
| Companies | Position | Start |
|---|---|---|
Scandibio Therapeutics AB
 Scandibio Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Scandibio Therapeutics AB is a Swedish company that specializes in omics data integration, including transcriptomics, proteomics, metabolomics, and metagenomics, using biological networks. Scandibio Therapeutics is based in Stockholm, SE, and was founded by Karin Marianne Hansson, who has been the CEO since incorporation. The private company also study host-microbiome interactions to understand whole body metabolism in health and diseases. The company employs the latest technology and science, such as genome-scale metabolic models, protein-protein interaction networks, transcriptional regulatory networks, signaling networks, metabolic co-factors, host metabolism, microbiome analysis, and clinical studies. | Chief Executive Officer | 2017-10-31 |
Amylonix AB
 Amylonix AB Pharmaceuticals: MajorHealth Technology Amylonix AB develops pharmaceuticals focused on the neurodegenerative area. Amylonix AB is based in Johanneshov, Sweden. It was founded in 2018 by Karin Marianne Hansson, who has been the CEO since 2018. | Founder | 2018-01-31 |
| Scandiedge Therapeutics AB | Founder | 2017-10-31 |
| Mariham Consulting AB | Chief Executive Officer | - |
| Protemedge AB | Founder | - |
| A05 Diagnostics AB | Chief Executive Officer | - |
Former positions of Karin Hansson
| Companies | Position | End |
|---|---|---|
| Q-LINEA AB | Director/Board Member | 2023-06-12 |
Atlas Antibodies AB
 Atlas Antibodies AB BiotechnologyHealth Technology Atlas Antibodies AB develops antibodies and reagents for Mass Spectrometry (MS)-based quantitative proteomics. Its project Human Protein Atlas aim to present an expression map of the complete human proteome. It offers characterized antibodies to various protein coding human genes; Triple A Polyclonals that are research grade rabbit polyclonal antibodies; and mouse monoclonal antibodies to selected proteins, as a complement to rabbit polyclonal antibodies. Its antibodies are used to study human proteins, for basic research purposes and clinical research in various disease areas, such as cancer and neurological brain diseases. The company was founded by Jan Fredrik Pontén, Karin Marianne Hansson, Henrik Wernérus, and Carl Erik Mathias Uhlén in 2006 and is headquartered in Stockholm, Sweden. | Chief Executive Officer | 2017-07-31 |
| Antibodies Incentive AB | Corporate Officer/Principal | - |
| ░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Training of Karin Hansson
| Royal Institute of Technology | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| Q-LINEA AB | Health Technology |
| INTERVACC AB | Health Technology |
| Private companies | 11 |
|---|---|
Affibody AB
 Affibody AB Miscellaneous Commercial ServicesCommercial Services Affibody AB conducts research and development services within biotechnology. It markets and sells licensed products and research findings to the pharmaceutical industry. The company was founded by Karin Nord in 1998 and is headquartered in Stockholm, Sweden. | Commercial Services |
Affibody Medical AB
 Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | Health Technology |
Atlas Antibodies AB
Atlas Antibodies AB BiotechnologyHealth Technology Atlas Antibodies AB develops antibodies and reagents for Mass Spectrometry (MS)-based quantitative proteomics. Its project Human Protein Atlas aim to present an expression map of the complete human proteome. It offers characterized antibodies to various protein coding human genes; Triple A Polyclonals that are research grade rabbit polyclonal antibodies; and mouse monoclonal antibodies to selected proteins, as a complement to rabbit polyclonal antibodies. Its antibodies are used to study human proteins, for basic research purposes and clinical research in various disease areas, such as cancer and neurological brain diseases. The company was founded by Jan Fredrik Pontén, Karin Marianne Hansson, Henrik Wernérus, and Carl Erik Mathias Uhlén in 2006 and is headquartered in Stockholm, Sweden. | Health Technology |
Atlas Therapeutics AB
 Atlas Therapeutics AB Pharmaceuticals: MajorHealth Technology Part of Alligator Bioscience AB, Atlas Therapeutics AB develops and manufactures antibody drugs. The company is based in Stockholm, Sweden. Atlas Therapeutics was acquired by Alligator Bioscience AB on October 18, 2013. | Health Technology |
| Antibodies Incentive AB | |
Scandibio Therapeutics AB
Scandibio Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Scandibio Therapeutics AB is a Swedish company that specializes in omics data integration, including transcriptomics, proteomics, metabolomics, and metagenomics, using biological networks. Scandibio Therapeutics is based in Stockholm, SE, and was founded by Karin Marianne Hansson, who has been the CEO since incorporation. The private company also study host-microbiome interactions to understand whole body metabolism in health and diseases. The company employs the latest technology and science, such as genome-scale metabolic models, protein-protein interaction networks, transcriptional regulatory networks, signaling networks, metabolic co-factors, host metabolism, microbiome analysis, and clinical studies. | Commercial Services |
Amylonix AB
Amylonix AB Pharmaceuticals: MajorHealth Technology Amylonix AB develops pharmaceuticals focused on the neurodegenerative area. Amylonix AB is based in Johanneshov, Sweden. It was founded in 2018 by Karin Marianne Hansson, who has been the CEO since 2018. | Health Technology |
| Scandiedge Therapeutics AB | |
| Mariham Consulting AB | |
| Protemedge AB | |
| A05 Diagnostics AB |
- Stock Market
- Insiders
- Karin Hansson
